Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?

× No keyword cloud information.

31 in total

Review 1. Do immune checkpoint inhibitors need new studies methodology?

Authors: Roberto Ferrara; Sara Pilotto; Mario Caccese; Giulia Grizzi; Isabella Sperduti; Diana Giannarelli; Michele Milella; Benjamin Besse; Giampaolo Tortora; Emilio Bria
Journal: J Thorac Dis Date: 2018-05 Impact factor: 2.895

2. How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated?

Authors: Miki Horiguchi; Michael J Hassett; Hajime Uno
Journal: Oncologist Date: 2018-09-10

3. Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?

Authors: Boris Freidlin; Edward L Korn
Journal: J Clin Oncol Date: 2019-10-24 Impact factor: 44.544

4. Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Authors: Omer Ben-Aharon; Racheli Magnezi; Moshe Leshno; Daniel A Goldstein
Journal: Oncologist Date: 2019-07-18

5. Design of non-inferiority randomized trials using the difference in restricted mean survival times.

Authors: Isabelle R Weir; Ludovic Trinquart
Journal: Clin Trials Date: 2018-08-03 Impact factor: 2.486

6. Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis.

Authors: Ariela R Orkaby; Michael W Rich; Ryan Sun; Eliah Lux; Lee-Jen Wei; Dae Hyun Kim
Journal: J Am Geriatr Soc Date: 2018-09-25 Impact factor: 5.562

7. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.

Authors: Kyongsun Pak; Hajime Uno; Dae Hyun Kim; Lu Tian; Robert C Kane; Masahiro Takeuchi; Haoda Fu; Brian Claggett; Lee-Jen Wei
Journal: JAMA Oncol Date: 2017-12-01 Impact factor: 31.777

8. Quantifying the totality of treatment effect with multiple event-time observations in the presence of a terminal event from a comparative clinical study.

Authors: Brian Claggett; Lu Tian; Haoda Fu; Scott D Solomon; Lee-Jen Wei
Journal: Stat Med Date: 2018-07-25 Impact factor: 2.373

9. Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes.

Authors: Hajime Uno; Miki Horiguchi; Michael J Hassett
Journal: Oncologist Date: 2019-11-19

10. Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer.

Authors: Guodong Zhang; Qing Xu; Xiangyun Zhang; Moran Yang; Yiying Wang; Mengdi He; Jiaqi Lu; Haiou Liu
Journal: Cancer Med Date: 2021-05-05 Impact factor: 4.452